Loading clinical trials...
Loading clinical trials...
A Phase I Open-label Study to Evaluate Safety and Immunologic Response of COMBIG-DC Administered Intratumorally in Patients With Metastatic Renal Cell Carcinoma
Conditions
Interventions
Combig-DC (allogeneic dendritic cells) Cancer Vaccine
Locations
1
Sweden
Dept of Oncology, University Hospital
Uppsala, Sweden
Start Date
February 1, 2012
Primary Completion Date
December 1, 2013
Completion Date
December 1, 2013
Last Updated
October 12, 2015
NCT06391099
NCT07227415
NCT06835972
NCT07175480
NCT05700461
NCT05122546
Lead Sponsor
Mendus
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions